E.U. paediatric MOG consortium consensus: Part 5 – Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders
Arlette L. Bruijstens, Eva‐Maria Wendel, Christian Lechner, Frederik Bartels, Carsten Finke, Markus Breu, Lorraine Flet‐Berliac, Aliénor de Chalus, C. Adamsbaum, Marco Capobianco, Laetitia Giorgi, Yael Hacohen, Cheryl Hemingway, Evangeline Wassmer, Ming Lim, Matthias Baumann, Ronny Wickström, Thaís Armangué, Kevin Rostásy, Kumaran Deiva, Rinze F. Neuteboom
Abstract
A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identification of monophasic and relapsing ADS forms different from MS predominantly in children. Due to the novelty of this antibody there are still challenges and controversies about its pathogenicity and best technique to detect it. In this manuscript we will discuss the recommendations and caveats on MOG antibody assays, role in the pathogenesis, and additionally discuss the usefulness of other potential new biomarkers in MOG-antibody associated disorders (MOGAD).